Nephron Announces FDA Approval of Ketorolac, Signaling New Phase of Growth
Nephron Announces FDA Approval of Ketorolac, Signaling New Phase of Growth Kennedy: Company Excited to Expand Generic Portfolio to Include Non-Respiratory Products News provided by Share this article WEST COLUMBIA, S.C., Dec. 22, 2020 /PRNewswire/ --ย Nephron Pharmaceuticals Corporation is celebrating another milestone. The company today announced Food and Drug Administration (FDA) approval of the Nephron Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 60 mg/2...
Source: prnewswire.com